[An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
Lang
Andreas
A
Kliniken Maria Hilf GmbH, Krankenhaus St. Franziskus, Klinik für Hämatologie, Onkologie und Gastroenterologie, Mönchengladbach.
Graeven
U
U
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D002455:Cell Division / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000188:drug therapy; D004067:Digestive System Neoplasms / Q000188:drug therapy*; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011956:Receptors, Cell Surface; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor